27 McCullough Dr. New Castle, DE, 19720 United StatesDeep expertise in complex and emerging chemistry Advanced small‑molecule programs spanning heterocycles, high‑purity monomers, deuterated and isotopically labeled compounds, metabolites, regulated/key starting materials, and complex intermediates. Emerging modalities include PROTACs, peptides, oligonucleotides, ADC linkers, and specialty materials. Strong scientific depth and rigor 150+ in‑house chemists, with over 80% holding PhDs, experienced in solving highly challenging synthetic, process development, and scale‑up problems. Our teams bring deep chemical insight and deliver consistently high‑quality results. U.S.-based Chemistry CRO & CDMO Headquartered in Delaware with more than 35 years of experience supporting drug discovery, development, and commercialization. Known for quality, reliability, and scientific rigor across pharma, biotech, and medical device programs. Robust IP, IT, and data protection Strong intellectual property protection supported by secure IT infrastructure, controlled access systems, and strict confidentiality practices to safeguard client data, processes, and proprietary technologies. Faster, lower‑risk development Scalable synthetic routes designed early to accelerate SAR cycles and reduce downstream development and scale‑up risk. Integrated delivery model Discovery, process development, and specialty manufacturing managed by unified scientific teams—minimizing handoffs and improving first‑time‑right execution. Seamless scale‑up Efficient transition from milligram quantities to multi‑kilogram production. Proven speed and reliability Trusted partner for time‑critical programs requiring rapid turnaround without compromising quality or scientific rigor. Hands‑on problem‑solving partner Frequently selected when other providers are unable to deliver viable or scalable synthetic solutions. Flexible engagement models Support available through both FTE and fee‑for‑service structures to align with evolving project needs. -Comprehensive small‑molecule synthesis capabilities, including: Heterocyclic compounds containing Nitrogen, Oxygen and Sulfur High‑purity monomers Deuterated compounds Stable‑isotope labeled compounds (^2H, ^13C, ^15N) Natural products Impurities and reference standards Metabolite synthesis (hydrolysis, oxidation, glucuronides, etc.) Protacs Broad experience with diverse ligase binders ((hetero)aryl-glutarimides, thalidomides, and (hetero)aryl-dihydrouracils) Proficient in PEG-amino amide/rigid/flexible linkers Optimized conjugation for multiple chemotypes: amides, O-/N-alkylation, C–C bonds, and sulfonamides Peptides and oligonucleotides (linear and cyclic using solid and liquid phase synthesis) Linker chemistry for ADC's Peptide-drug conjugate Analytical services like method development Stability studies Polymorph and salt screen Regulated starting materials (RSM) Key starting materials (KSM) Amino Acids, Chiral Chemistry-Catalysis, Asymmetric Synthesis, Diastereomeric Salt Crystallization, Enzymatic Resolutions, Diels-Alder, Distillation, Energetic Chemistries, Halogenation, Chloromethylation, Hydrogenation, Low Temperature/Commercial Scale, Nucleosides and Sugars, Organometallic Chemistry – Grignard, Alkylithiums, Ullman, Oxidation (Classical, TEMPO/NaOCl, Pyr-SO3), Palladium and Nickel Catalyzed – Heck, Suzuki and related, Steroids , Sulfonation, Thiophosgenation, Phosgenation, High Containment/Cytotoxic Capabilities upto OEB 4,